My doctor's contact information

My doctor prescribing Zinbryta can be contacted at the number below. Other doctors or healthcare professionals involved in my care are also listed below.

	Name	Phone number
Neurologist		
General Practitioner		
MS Nurse		

Biogen.

Version number: 2.
Approval date: January 2018.
DA-PAN-0076a

My information

	:
Start of Zinbryta treatment:	
My name:	
Name and phone number of car	egiver (in case of emergency):

Doctors: See Zinbryta Summary of Product Characteristics and medicines.ie (Ireland) or medicines.org.uk/emc (UK) for more information.



Patient card

Please show this card to all emergency and healthcare professionals.

I am being treated with Zinbryta for multiple sclerosis (MS), and my liver function is being monitored at least monthly during treatment and for 6 months after I receive my last dose.

Why you have this card and what to do with it

The patient card contains important safety information that you need to be aware of.

Please read it carefully.

How long to keep this card

Keep this card with you at all times and for 6 months after you receive your last dose. This is because side effects may occur during that time.

What Zinbryta® is used for and what you need to know before use

Zinbryta 150 mg is used to treat certain types of relapsing forms of MS.

Zinbryta is injected under the skin every month.

Please read the package leaflet for more information

Liver side effects

Zinbryta may cause liver problems, which can be unpredictable and could be life-threatening or potentially result in death. Serious liver problems can occur both early after starting treatment with Zinbryta, any time during treatment and several months after stopping treatment. Please discuss this side effect with your prescribing doctor or any other treating healthcare professional.

You should tell your doctor about any other medicines you are receiving, including non-prescription products and herbal supplements.

Please pay attention to the following signs and symptoms, which may indicate liver problems. Only a healthcare professional can tell if these are signs of a possible liver problem or due to another cause.

Signs and symptoms of possible liver problems

If you experience any of the following, contact your doctor **immediately**:

- · feeling sick (nausea)
- · being sick (vomiting)
- stomach pain
- · increased tiredness
- · loss of appetite (anorexia)
- your skin or the whites of your eyes turn yellow
- · dark (tea-coloured) urine

Your MS doctor may stop your treatment with Zinbryta and refer you to a liver specialist, if you are suspected of having possible liver problems.

What to do if you suspect liver problems

Seek medical attention **immediately** if you have any of these signs or symptoms. Even what may seem to be mild symptoms can lead to life-threatening conditions or death if not promptly addressed.

Information on testing for liver problems

In order to make decisions about your MS treatment, your doctor will take a blood sample for liver tests before you begin treatment with Zinbryta, and at least every month during treatment, and for up to 6 months after your last dose.

It is very important that you have these regular blood tests. If you do not undergo your scheduled blood tests, your doctor may stop treatment with Zinbryta.

For healthcare providers

This patient is being treated with Zinbryta, which is associated with serious (including possibly life-threatening or fatal) hepatic injury.

▼Reporting of side effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report them directly via the national reporting system at: www.mhra.gov.uk/yellowcard (UK), or if in Ireland, via

HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6712517. Website: www.hpra.ie; E-mail: medsafetv@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

